SS-31 (Elamipretide): The Mitochondrial Peptide in Trials
A genuinely investigational compound that has run real clinical trials — and largely missed its primary endpoints. A useful benchmark.
Most peptides marketed for optimization have little real clinical development behind them. Elamipretide, often referred to by its research name SS-31, is different. It is an investigational mitochondrial-targeting peptide that has moved through genuine, registered clinical trials in defined patient populations. That track record makes it a useful benchmark — an example of what serious peptide development actually looks like, including how often it ends in disappointing results.
What it is designed to do
Mitochondria are the energy producers inside cells, and their inner membranes contain a lipid called cardiolipin that is essential for efficient energy production. Elamipretide is designed to localize to that inner membrane and interact with cardiolipin, with the goal of stabilizing mitochondrial function under stress or disease. The thesis is that protecting mitochondrial energetics could help conditions where those organelles are failing.
A compound being “in trials” is meaningful — but it is not the same as “proven.” Trials exist to find out whether a promising mechanism delivers in humans, and elamipretide’s pivotal trials repeatedly did not meet their primary endpoints.
What the trials actually showed
Two of the most informative studies illustrate the pattern.
| Trial | Population | Design | Primary result |
|---|---|---|---|
| MMPOWER-3 (Neurology, 2023) | Primary mitochondrial myopathy, n=218 | 24-week RCT, 40 mg/day subcutaneous vs placebo | Did not meet endpoints; 6-minute walk difference −3.2 m (p=0.69) |
| Barth syndrome trial (Genetics in Medicine, 2020) | Barth syndrome, n=12 | Crossover RCT, 40 mg/day, then open-label extension | Neither primary endpoint (6MWT, symptom score) met in the randomized phase |
In the small Barth syndrome study, some measures appeared to improve during the open-label extension (for example, a reported ~25% gain in walk distance by week 36). But open-label, uncontrolled improvement is the weakest tier of evidence, and the randomized, blinded comparison — the part that controls for placebo and expectation — was negative. Stealth BioTherapeutics later received a Refusal to File letter from the FDA for that program.
Why it is still a good benchmark
Comparing elamipretide to the typical optimization peptide is instructive:
- It targets a specific, well-characterized biological mechanism (cardiolipin).
- It has been tested in defined patient populations under regulatory oversight.
- Its results — including the failures — are published in journals like Neurology and Genetics in Medicine and openly scrutinized.
That is the bar. When a marketed peptide cannot point to anything resembling this — registered trials, defined endpoints, published outcomes — the gap tells you how speculative it really is.
The takeaway
Elamipretide is a genuinely serious investigational mitochondrial peptide — and a cautionary one. Its mechanism is sound and its development real, yet its pivotal randomized trials in mitochondrial myopathy and Barth syndrome largely missed their primary endpoints. “Promising” and “unproven” are both true at once. Use it as a yardstick: a compound this rigorously studied still struggled to show benefit, which should make you far more skeptical of unstudied peptides making confident claims.